Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Eoflow Has been ordered by the U.S. Court to pay $452M as damages. Celltrion has submitted clinical trial application for CT-P44 (Darzalex biosimilar) to the FDA.</li>
<li>Takeda Pharmaceutical entered into an exclusive licensing agreement to develop and commercialize a late-stage oncology drug candidate. Medipal and JCR Pharmaceuticals initiated the Phase I/II trial of JR-446 in Japan.</li>
<li>SanBio has completed second production run for Akuugo suspension for intracranial implantation. Aurobindo Pharma’s U.S. arm Eugia has received final approval from the FDA to manufacture and market Pazopanib Tablets.</li>
</ul>


Eoflow Has been ordered by the U.S. Court to pay $452M as damages. Celltrion has submitted clinical trial application for CT-P44 (Darzalex biosimilar) to the FDA.
Takeda Pharmaceutical entered into an exclusive licensing agreement to develop and commercialize a late-stage oncology drug candidate. Medipal and JCR Pharmaceuticals initiated the Phase I/II trial of JR-446 in Japan.
SanBio has completed second production run for Akuugo suspension for intracranial implantation. Aurobindo Pharma’s U.S. arm Eugia has received final approval from the FDA to manufacture and market Pazopanib Tablets.


APAC Healthcare Weekly (Dec 8)- Eoflow, Celltrion, Takeda, Medipal, SanBio, Aurobindo Pharma

<ul>
<li>Eisai Announced that global revenue of Leqembi in Q2FY25 was ¥10B, up 1.6x than Q1FY25. Takeda Pharma announced positive interim results from a Phase 3 study.</li>
<li>Shionogi’s COVID-19 drug was effective in reducing transmission of the disease. JCR Pharmaceuticals initiated first patient dosing in Japan in the Phase I clinical trial of JR-441.</li>
<li>Celltrion signed a contract with a U.S. GPO to list Zymfentra on private insurance formularies, which will expand the drug's coverage to 90%+ of the U.S. health insurance market.</li>
</ul>


Eisai Announced that global revenue of Leqembi in Q2FY25 was ¥10B, up 1.6x than Q1FY25. Takeda Pharma announced positive interim results from a Phase 3 study.
Shionogi’s COVID-19 drug was effective in reducing transmission of the disease. JCR Pharmaceuticals initiated first patient dosing in Japan in the Phase I clinical trial of JR-441.
Celltrion signed a contract with a U.S. GPO to list Zymfentra on private insurance formularies, which will expand the drug's coverage to 90%+ of the U.S. health insurance market.


APAC Healthcare Weekly (Nov 3)- Eisai, Takeda, Shionogi, Astellas Pharma, Celltrion, Wuxi AppTec

<ul>
<li>
<a href="https://www.smartkarma.com/entities/samsung-biologics-co-ltd" target="_blank" data-smartkarma-citation="entities:22932:1" rel="noopener">Samsung Biologics (207940 KS)</a> signed a contract manufacturing agreement worth KRW1.7T ($1.2B) with an Asian pharmaceutical company. <a href="https://www.smartkarma.com/entities/celltrion-inc" target="_blank" data-smartkarma-citation="entities:991:1" rel="noopener">Celltrion Inc (068270 KS)</a> has announced KRW100B ($72M) share buyback, starting October 28.</li>
<li>
<a href="https://www.smartkarma.com/entities/astellas-pharma-inc" target="_blank" data-smartkarma-citation="entities:6091:1" rel="noopener">Astellas Pharma (4503 JP)</a> received FDA approval for Vyloy for gastric cancer. <a href="https://www.smartkarma.com/entities/shionogi-co-ltd" target="_blank" data-smartkarma-citation="entities:19535:1" rel="noopener">Shionogi &amp; Co (4507 JP)</a> received FDA Fast Track designation for its RSV drug candidate, S-337395.</li>
<li>
<a href="https://www.smartkarma.com/entities/zai-lab-ltd-94df40cf-c15e-462f-b3de-8d2d434ae935" target="_blank" data-smartkarma-citation="entities:36261:1" rel="noopener">Zai Lab (9688 HK)</a> announced positive topline data from global Phase 1a/1b study of ZL-1310 in small cell lung cancer. <a href="https://www.smartkarma.com/entities/legend-biotech-corp" target="_blank" data-smartkarma-citation="entities:28963:1" rel="noopener">Legend Biotech Corp (LEGN US)</a> sheds Genscript Biotech as its majority shareholder.</li>
</ul>



Samsung Biologics (207940 KS) signed a contract manufacturing agreement worth KRW1.7T ($1.2B) with an Asian pharmaceutical company. Celltrion Inc (068270 KS) has announced KRW100B ($72M) share buyback, starting October 28.

Astellas Pharma (4503 JP) received FDA approval for Vyloy for gastric cancer. Shionogi &amp; Co (4507 JP) received FDA Fast Track designation for its RSV drug candidate, S-337395.

Zai Lab (9688 HK) announced positive topline data from global Phase 1a/1b study of ZL-1310 in small cell lung cancer. Legend Biotech Corp (LEGN US) sheds Genscript Biotech as its majority shareholder.


APAC Healthcare Weekly (Oct 27)- Samsung Biologics, Celltrion, Astellas, Otsuka, Legend, and Zai Lab

'Quantamental' Japan Specialist, LightStream Research

Campbell Gunn

'Quantamental' Japan Specialist

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

<p>Thursday saw only four micro-cap results, so we will again focus on just the forecasts and revisions, of which there were sixteen, with ten companies scoring positively. Top of the list is <a href="https://www.smartkarma.com/entities/jcr-pharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:20126:1" rel="noopener">JCR Pharmaceuticals (4552 JP)</a>, with a perfect '30'; however, the shares have been overbought for over a year, and at a trailing EV/OP of 81 times, the upside will be limited. In the <strong>DETAIL</strong> section below, we will comment on <a href="https://www.smartkarma.com/entities/misumi-group-inc" target="_blank" data-smartkarma-citation="entities:15017:1" rel="noopener">Misumi (9962 JP)</a> and <a href="https://www.smartkarma.com/entities/j-front-retailing-co-ltd" target="_blank" data-smartkarma-citation="entities:8947:1" rel="noopener">J Front Retailing (3086 JP)</a>. </p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/197/207/original/image_21281428221616706680030.png?1616706680" class="editor-image img-responsive" data-smartkarma-image-id="197207"></figure><p></p><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/197/208/original/image_67212866131616707233344.png?1616707233" class="editor-image img-responsive" data-smartkarma-image-id="197208"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/197/209/original/image_93705278141616707542472.png?1616707543" class="editor-image img-responsive" data-smartkarma-image-id="197209"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/197/210/original/image_68981801851616707599632.png?1616707599" class="editor-image img-responsive" data-smartkarma-image-id="197210"></figure>

Thursday saw only four micro-cap results, so we will again focus on just the forecasts and revisions, of which there were sixteen, with ten companies scoring positively. Top of the list is JCR Pharmaceuticals (4552 JP), with a perfect '30'; however, the shares have been overbought for over a year, and at a trailing EV/OP of 81 times, the upside will be limited. In the DETAIL section below, we will comment on Misumi (9962 JP) and J Front Retailing (3086 JP). 

🇯🇵 JAPAN • Revisions 03/​​​​​​25 > Misumi & J. Front Retailing

<div>
<p style="text-align: center;"><strong>• BEST &amp; WORST •</strong></p>
<p>The best and worst pair from yesterday's announcements is call centre <a href="https://www.smartkarma.com/entities/bell-system24-holdings-inc" target="_blank" data-smartkarma-citation="entities:27224:1" rel="noopener">Bell System24 (6183 JP)</a> and the very Overbought <a href="https://www.smartkarma.com/entities/jcr-pharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:20126:1" rel="noopener">JCR Pharmaceuticals (4552 JP)</a>.</p>
<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/163/985/original/2020-10-08_05-56-30.png?1602104205" class="editor-image img-responsive" data-smartkarma-image-id="163985"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/163/986/original/2020-10-08_05-55-56.png?1602104228" class="editor-image img-responsive" data-smartkarma-image-id="163986"></figure><div class="content-caption">Source for all charts &amp; tables: Japan Analytics</div>
<strong>AEON GROUP</strong> - Wednesday was 'Aeonday' as the majority of group companies reported, and a majority are still showing trailing losses. Parent Aeon's revenues were stable but trailing operating income is still declining at a double-digit rate, something the market is content to 'look through'. At 2.33 Aeon's Relative Price Score is close to a fifteen-year high; its PBR is twice that of <a href="https://www.smartkarma.com/entities/seven-i-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:1041:1" rel="noopener">Seven &amp; I (3382 JP)</a> whose Residual Core Return is six times Aeon's. We would trade the 'pair'.</div><div></div><div>
<figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/163/987/original/2020-10-08_06-17-52.png?1602105492" class="editor-image img-responsive" data-smartkarma-image-id="163987"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/163/988/original/2020-10-08_06-22-24.png?1602105757" class="editor-image img-responsive" data-smartkarma-image-id="163988"></figure><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/163/989/original/2020-10-08_06-25-33.png?1602105947" class="editor-image img-responsive" data-smartkarma-image-id="163989"></figure><p></p>
</div><div>
<hr>
<p style="text-align: center;"><strong>DAILY STATS</strong></p>
</div><hr><div><p style="text-align: center;"><strong>21 Quarterly Results</strong></p></div><div><ul style="list-style-type: disc;">
<li><p><strong>Results Score:</strong> 62% Positive / 10% Neutral / 28% Negative</p></li>
<li><p><strong>Average Results Score Change:</strong> +1.5 points</p></li>
<li><p><strong>Average % Change in Revenue:</strong> +8.2% Quarter YoY / +9.1% Rolling TTM YoY </p></li>
<li><p><strong>Average Operating Profit Margin Change:</strong> -3.0ppt</p></li>
<li><p><strong>Percentage Making Quarterly Losses:</strong> 33%</p></li>
</ul></div><hr><div><p style="text-align: center;"><strong>15 Annual • 3 Interim Forecasts/Revisions</strong></p></div><div><ul style="list-style-type: disc;">
<li><p><strong>Annual Forecast/Revision Score:</strong> 47% Positive / 6% Neutral / 47% Negative</p></li>
<li><p><strong>Interim Forecast/Revision Score Change:</strong> 0% Positive / 0% Neutral / 100% Negative</p></li>
<li><p><strong>Average Forecast/Revision Score Change:</strong> -6.8 point</p></li>
</ul></div>


• BEST &amp; WORST •
The best and worst pair from yesterday's announcements is call centre Bell System24 (6183 JP) and the very Overbought JCR Pharmaceuticals (4552 JP).
Source for all charts &amp; tables: Japan Analytics
AEON GROUP - Wednesday was 'Aeonday' as the majority of group companies reported, and a majority are still showing trailing losses. Parent Aeon's revenues were stable but trailing operating income is still declining at a double-digit rate, something the market is content to 'look through'. At 2.33 Aeon's Relative Price Score is close to a fifteen-year high; its PBR is twice that of Seven &amp; I (3382 JP) whose Residual Core Return is six times Aeon's. We would trade the 'pair'.



DAILY STATS
21 Quarterly Results
Results Score: 62% Positive / 10% Neutral / 28% Negative
Average Results Score Change: +1.5 points
Average % Change in Revenue: +8.2% Quarter YoY / +9.1% Rolling TTM YoY 
Average Operating Profit Margin Change: -3.0ppt
Percentage Making Quarterly Losses: 33%
15 Annual • 3 Interim Forecasts/Revisions
Annual Forecast/Revision Score: 47% Positive / 6% Neutral / 47% Negative
Interim Forecast/Revision Score Change: 0% Positive / 0% Neutral / 100% Negative
Average Forecast/Revision Score Change: -6.8 point


🇯🇵 JAPAN • Results & Revisions - 10/​​​​​​​​07 Aeon Group, BS24, Welcia, JCR Pharma

Japan

JCR Pharmaceuticals Co., Ltd. develops, produces, and sells pharmaceutical products and raw materials.  The Company also sells equipment for hospital and laboratory use.  JCR Pharmaceuticals' products include drug for leukemic diseases and hormonal agents including genetically engineered human somatotrophic hormone (growth hormone) and gonadotropic hormone.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jcr Pharmaceuticals (4552 JP)

APAC Healthcare Weekly (Dec 8)- Eoflow, Celltrion, Takeda, Medipal, SanBio, Aurobindo Pharma

The insight covers key developments in prominent APAC healthcare companies. These developments are expected to impact the financials of the...

Tina Banerjee

APAC Healthcare Weekly (Nov 3)- Eisai, Takeda, Shionogi, Astellas Pharma, Celltrion, Wuxi AppTec

Large APAC healthcare companies are reporting mixed earnings. Demography will play a key role in ensuring how the overall domestic demand scenario...

Tina Banerjee

APAC Healthcare Weekly (Oct 27)- Samsung Biologics, Celltrion, Astellas, Otsuka, Legend, and Zai Lab

Samsung Biologics secures largest ever contract, Celltrion announced KRW100B buyback, Astellas Pharma got label expansion approval for Vyloy,...

Tina Banerjee

🇯🇵 JAPAN • Revisions 03/25 > Misumi & J. Front Retailing

Thursday saw only four micro-cap results, so we will again focus on just the forecasts and revisions, of which there were sixteen, with ten...

Campbell Gunn

🇯🇵 JAPAN • Results & Revisions - 10/07 Aeon Group, BS24, Welcia, JCR Pharma

• BEST & WORST • The best and worst pair from sday's announcements is consumer electronics retailer Bic Camera (3048 JP) and Japan's largest...

Campbell Gunn

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

APAC Healthcare Weekly (Dec 8)- Eoflow, Celltrion, Takeda, Medipal, SanBio, Aurobindo Pharma

The insight covers key developments in prominent APAC healthcare companies. These developments are expected to impact the financials of the...

Tina Banerjee

APAC Healthcare Weekly (Nov 3)- Eisai, Takeda, Shionogi, Astellas Pharma, Celltrion, Wuxi AppTec

Large APAC healthcare companies are reporting mixed earnings. Demography will play a key role in ensuring how the overall domestic demand scenario...

Tina Banerjee

APAC Healthcare Weekly (Oct 27)- Samsung Biologics, Celltrion, Astellas, Otsuka, Legend, and Zai Lab

Samsung Biologics secures largest ever contract, Celltrion announced KRW100B buyback, Astellas Pharma got label expansion approval for Vyloy,...

Tina Banerjee

🇯🇵 JAPAN • Revisions 03/​​​​​​25 > Misumi & J. Front Retailing

Thursday saw only four micro-cap results, so we will again focus on just the forecasts and revisions, of which there were sixteen, with ten...

Campbell Gunn

🇯🇵 JAPAN • Results & Revisions - 10/​​​​​​​​07 Aeon Group, BS24, Welcia, JCR Pharma

• BEST & WORST • The best and worst pair from sday's announcements is consumer electronics retailer Bic Camera (3048 JP) and Japan's largest...

Campbell Gunn

🇯🇵 JAPAN • Revisions 03/25 > Misumi & J. Front Retailing

🇯🇵 JAPAN • Results & Revisions - 10/07 Aeon Group, BS24, Welcia, JCR Pharma